Momenta Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
MNTA Momenta Pharmaceuticals Inc
LMT Lockheed Martin Corp
POL PolyOne Corp
HAS Hasbro Inc
JBLU JetBlue Airways Corp
CDNS Cadence Design Systems Inc
IVAC Intevac Inc
HLIT Harmonic Inc
MPWR Monolithic Power Systems Inc
MXIM Maxim Integrated Products Inc

Health Care : Biotechnology | Small Cap BlendCompany profile

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Day's Change
0.21 (1.46%)
B/A Size
Day's High
Day's Low

Today's volume of 111,845 shares is on pace to be much lighter than MNTA's 10-day average volume of 320,501 shares.


UPDATE: Enjoy 2019 while it lasts, because 'the Big Top' is coming, B. of A. strategist warns

1:31 pm ET September 14, 2019 (MarketWatch)

By Shawn Langlois, MarketWatch

In the 2010s, it was low taxes, inequality and bonuses. Over the next decade, the script flips to high taxes, redistribution and universal basic income.

Those are just some of the shifting themes that Bank of America(BAC) , in a note led by top strategist Michael Hartnett, says investors will have to grapple with as the long-running bull market limps into 2020.

Here are the others:

"We are bullish on risk assets in 2019 as bearish investor sentiment and the irrationality of central banks and bond markets allow an 'overshoot' in credit and equity prices," he wrote. "We are bearish on risk assets in 2020 as recession / policy impotence / bond bubble risks induce Big Top in credit and equities."

Hartnett explained that the most contrarian trade in the next 10 years is "long inflation," and as you can see, that would be quite a reversal:

"The 2020s are likely to witness a more forceful attempt to create inflation," he said. "Even the slightest sign of success will lead to dramatic rotation... away from the deflationary winners of the 2010s to the inflationary losers."

Overall, Hartnett says the upcoming war on inequality will be bearish for stocks, leading to an overshoot in gold prices .

But, for the short term, there's reason for bulls to be hopeful.

B. of A.'s Bull & Bear Indicator, which tracks 18 measurements on asset flow, sentiment, and price, is flashing a contrarian buy signal that hasn't been seen since way back in January. The drop in the reading was driven in large part by asset flows out of equity and emerging market debt, Harnett said.

The indicator has a solid track record of predicting what's next. Since 2000, global stocks rose a median 6.3% in the three months after such a buy signal was triggered, while 10-year Treasury yields increased 50 basis points.

The current signal implies that the S&P 500 index is likely to retest the all-time above the 3,000 level. At least check, the broad market gauge was up 25 points at 2,931 during Wednesday's rebound.

-Shawn Langlois; 415-439-6400;

(END) Dow Jones Newswires

September 14, 2019 13:31 ET (17:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.